Zenas BioPharma (ZBIO) Other Non-Current Assets (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Other Non-Current Assets of $14.5 million for Q1 2026, up 6854.55% year-over-year from $209000.0 in Q1 2025, and up 5.26% quarter-over-quarter from $13.8 million in Q4 2025.
Zenas BioPharma (ZBIO) Other Non-Current Assets (2023 - 2026) Analysis & Trends
Zenas BioPharma's Other Non-Current Assets history runs 4 years deep, the most recent figure standing at $14.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 6854.55% year-over-year to $14.5 million; the TTM figure through Mar 2026 stood at $14.5 million (up 6854.55% YoY), while the FY2025 annual figure was $13.8 million, up 7.41% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $14.5 million, up from $13.8 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $14.5 million in Q1 2026, with the low at $83000.0 in Q3 2025.
- The 4-year median for Other Non-Current Assets is $5.8 million (2023), against an average of $6.6 million.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets dropped 6.74% in 2025, then jumped 6854.55% in 2026.
- Zenas BioPharma's Other Non-Current Assets stood at $5.8 million in 2023, then surged by 122.11% to $12.9 million in 2024, then rose by 7.41% to $13.8 million in 2025, then grew by 5.26% to $14.5 million in 2026.
- Business Quant data shows ZBIO's Other Non-Current Assets at $14.5 million in Q1 2026, $13.8 million in Q4 2025, and $83000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | 16.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.29 Mn |
| Mar 31, 2026 | 14.54 Mn |
| Dec 31, 2025 | 13.81 Mn |
| Sep 30, 2025 | 83,000.00 |
| Jun 30, 2025 | 11.71 Mn |
| Mar 31, 2025 | 209,000.00 |
| Dec 31, 2024 | 12.86 Mn |
| Sep 30, 2024 | 89,000.00 |
| Dec 31, 2023 | 5.79 Mn |
| Sep 30, 2023 | 86,000.00 |